Neoadjuvant SACT
Refer to local SACT protocols for detail on the dosing and administration of specific regimens.
Throughout the patient pathway, consideration should be given to patient preference, performance status and other relevant patient factors.
Patient eligibility and suitability for available clinical trials should be considered and discussed with individual patients as appropriate.
Author | Nicola Steele (on behalf of SACT subgroup) | Reviewer | John Maclay |
Date of creation |
03/10/2024 |
Version number | 1.0 |
Review Date | 20/09/2026 | Contact |
The printing of visual pathways is strongly discouraged, due to the inability to print all relevant information contained within and behind the pathways. Any user choosing to do so must acknowledge that the information may be incomplete and that essential context may be missing from a printed or reproduced pathway.